suPARnostic® in the Laboratory

When working in the laboratory the main goal is to provide high quality results in the fastest possible way.
If new tests are implemented, they need to fit into already established processes.

The Clinical Biochemistry Department is a pivotal department, as its performance is key in assisting clinicians arriving to a sound diagnostic conclusion.

A fast turnaround time is needed to optimize clinical decision making and allow timely patient care.
Any test that can be run from the Clinical Biochemistry Department or core labs on the high-throughput turbidimetric platform is preferable.

By making the suPAR measurement available on a fully automated turbidimetric platform, you can support the hospitals’ desire to streamline their processes and keeping the turnaround time short.

What is a suPAR test?

The suPARnostic® test provides information on the extent of activation of our immune system.

The suPAR-level can, across diseases, evaluate the seriousness of disease and is associated with morbidity and mortality:
– A low suPAR level suggests a discharge decision
– A high suPAR level indicates disease progression, high risk of readmission and mortality

These patients can be identified earlier with suPARnostic® than what is possible with the current risk scores.

Standardized and automated test

The suPARnostic® TurbiLatex test is a ready-to-use kit with Reagents, Calibrators and Controls.

suPARnostic® TurbiLatex is validated for the Roche Diagnostics Cobas c501/c502 and c701/c702 biochemistry analysers.
Validations on Siemens and Abbott systems are in progress.

Installation of the suPARnostic® TurbiLatex protocol is easy and straight forward and it is easy to implement in the current work flow as a new routine test.

Why is it important to have a suPAR test on this platform?

Using suPAR as a clinical routine biomarker in the ED will make a significant difference for;

  • Patients
    o Identify those who have a good prognosis (low suPAR level) who can be discharged without increased risk of readmission and mortality
    o Identify those with chronic inflammation (elevated suPAR level) with increased risk of disease severity, readmission and mortality, who should be treated without delay
  • Clinicians
    o Eliminate doubt – when a fast, clinical judgement is needed, suPAR supports the decision to discharge a patient
  • Emergency Department
    o Shorten the average patient-length-of-stay
    o Discharge more patients within 24 hours
    o Free up beds and reduce crowding in ED
  • Hospital Administration
    o Significant cost savings

Three suPARnostic® tests are available:

suPARnostic® TurbiLatex Test – for the high throughput laboratories servicing Emergency Departments
suPARnostic® Quick Triage – a Point of Care Solution
suPARnostic® ELISA – mainly used for research purposes

Read more about the suPARnostic® products and why it is such an important marker for risk stratification that can help the clinicians in prioritizing and potentially saving lives:

suPARnostic® Products

Using suPAR as a Clinical Aid

suPAR biomarker and biology